South Africa’s Medical Cannabis Export Push: The Players, the Markets, and the Race to Compete with Canada

South Africa’s medical cannabis sector has moved from early licensing experiments to a functioning, if still modest, export industry. While Canada continues to dominate global supply into Europe, a cluster of SAHPRA-licensed South African cultivators and processors is steadily increasing shipments of high-THC flower to Germany, Australia, the United Kingdom and other regulated markets. The story is no longer whether South Africa can export medical cannabis — it is how far and how fast the country can scale while meeting the world’s strictest quality and compliance standards.

This article maps the current state of play: the main destination markets, the leading South African players, the competitive advantages and structural constraints, and the wider implications for the country’s still-unfinished domestic cannabis framework.

The Global Context: Germany as the Prize

Germany is the gravitational centre of the international medical cannabis trade. In 2025 the country imported approximately 201 tonnes of medical cannabis flower — nearly triple the previous year’s volume. Canada supplied roughly half of that total. Portugal functioned as the primary European processing and re-export hub. A second tier of suppliers, including Denmark, North Macedonia, Australia, Colombia and South Africa, filled the remainder.

South African volumes remain small in absolute terms but are growing. Quarterly shipments to Germany rose notably in late 2025, and early 2026 figures suggest the full-year total will exceed the previous year’s roughly 3,700 kg. Australia has also been a meaningful destination: imports from South Africa climbed from negligible levels in 2021 to nearly 5 tonnes in 2024 before settling slightly lower in 2025. The United Kingdom has shown steady growth, with South African shipments rising into the low thousands of kilograms.

These numbers place South Africa in the emerging-supplier category rather than among the volume leaders. Yet the trajectory matters. German importers are actively diversifying away from over-reliance on Canadian and Portuguese supply. Producers that can consistently deliver EU-GMP-aligned or equivalent quality, non-irradiated flower, and reliable logistics are finding buyers.

South Africa’s Export Architecture

Medical cannabis cultivation and export in South Africa is regulated by the South African Health Products Regulatory Authority (SAHPRA) under the Medicines and Related Substances Act. Operators require section 22C licences for cultivation, manufacturing and, where relevant, export. Good Agricultural and Collection Practices (GACP) are the baseline; many serious exporters are pushing toward full EU-GMP equivalence or working through EU-based intermediaries that hold the necessary certifications.

The sector is capital-intensive. Indoor and high-tech greenhouse facilities dominate the export-oriented segment because they offer the environmental control and traceability that European and Australian regulators demand. Outdoor and simpler greenhouse models struggle to meet microbial and consistency standards without expensive post-harvest interventions.

The Big Players

A relatively small group of companies accounts for the bulk of South Africa’s visible export activity.

Nexus Pharma has positioned itself as a supply-chain aggregator and vertically integrated player. CEO Johan Slabber has been one of the most public voices arguing that South Africa can compete on quality rather than pure price. The company works with multiple SAHPRA-licensed cultivators, handles international compliance, and has secured offtake relationships into Germany. It is developing additional processing capacity and has been linked to multi-tonne supply discussions with European buyers.

BioCann (Limpopo) operates one of the larger indoor cultivation footprints in the country and has invested heavily in moving from GACP toward EU-GMP readiness. The company emphasises controlled genetics (including Canadian-sourced lines with strong digital traceability), pest-management systems that reduce or eliminate the need for irradiation, and B2B supply to licensed pharmaceutical facilities abroad. BioCann has shipped to Germany, the UK and Australia.

MedCan was among the earlier movers in high-THC flower exports and is frequently cited as one of the first South African companies to reach the UK market. It operates indoor GMP-oriented facilities and focuses on pharmaceutical-grade dried flower.

Cilo Cybin Pharmaceutical (part of Cilo Cybin Holdings) is notable as one of the few JSE-listed entities with a clear medical-cannabis focus. It has highlighted combined GACP licensing and is building a presence in the formal pharmaceutical channel.

Other names that appear regularly in industry discussions include Biogenetics Labs (emphasis on high-cannabinoid, low-pesticide profiles suited to European requirements), CannaBudGrow (recently linked to direct supply into German pharmacies under branded flower such as “Supernova”), and a longer tail of smaller licensed cultivators that sell into aggregators or pursue direct export relationships.

The common thread among the serious exporters is investment in compliance infrastructure, controlled-environment cultivation, and relationships with European importers or wholesalers who can navigate the final mile into pharmacies.

Competitive Advantages

South African operators frequently cite three structural advantages:

1.  Cost base — Labour, energy (in some configurations) and certain input costs remain lower than in Canada or Western Europe.

2.  Climate and counter-seasonality — The Southern Hemisphere growing calendar can complement Northern Hemisphere supply cycles.

3.  Quality positioning — Several producers emphasise non-irradiated flower, strong terpene profiles, and pest-control methods (including biological controls) that appeal to buyers tired of over-processed product.

These advantages are real but not automatic. Meeting EU microbial limits, maintaining batch-to-batch consistency, and sustaining the documentation trail required by importers demand continuous investment. The companies that treat compliance as a core competency rather than a hurdle are the ones appearing in export statistics.

Constraints and Risks

The path is not frictionless. Key constraints include:

•  The high cost and long timeline of achieving and maintaining EU-GMP or equivalent status.

•  Limited domestic processing and packaging capacity at pharmaceutical grade.

•  Logistics and cold-chain reliability for long-haul shipments.

•  Currency volatility and the working-capital intensity of export cycles.

•  The still-narrow domestic medical market, which leaves most licensed producers heavily dependent on foreign offtake.

There is also a strategic tension. The same regulatory system that enables medical export remains largely closed to broad domestic adult-use commercialisation. Export success therefore sits alongside a domestic policy environment that continues to generate enforcement actions against unlicensed activity and leaves most ordinary South Africans without legal retail access.

Market Outlook

Germany will remain the primary volume opportunity for the next several years. Australia and the UK offer secondary but valuable channels, particularly for producers who can meet their distinct regulatory expectations. Longer-term upside exists if other European medical markets expand and if South African operators move further up the value chain into extracts, finished pharmaceutical products, or branded flower with stronger pricing power.

Volume growth is likely to be steady rather than explosive. The companies that combine reliable quality, transparent compliance, and credible commercial relationships will capture the majority of the opportunity. Those that cannot clear the regulatory and operational bar will remain confined to the domestic grey market or exit the sector.

Broader Implications

South Africa’s medical cannabis export story is one of the few bright spots in an otherwise incomplete formalisation landscape. It demonstrates that local operators can meet international pharmaceutical standards and compete for share in the world’s largest medical markets. At the same time, it highlights the dual-track reality: a capital-intensive, compliance-heavy export tier coexists with a large informal domestic market and a still-unfinished private-use and commercial adult-use framework.

For policymakers, the export sector offers evidence that regulatory rigour can unlock foreign-exchange earnings and skilled employment. For the broader cannabis community, it raises familiar questions about inclusion: whether the knowledge, genetics and cultivation expertise that exist outside the licensed export channel will ever find viable legal pathways, or whether the formal industry will remain a relatively small, high-barrier enclave.

The next phase will be determined less by additional licences than by execution — consistent quality, reliable supply, and the ability to deepen relationships in Germany and beyond. South Africa has a seat at the table. Turning that seat into a meaningful share of the global medical cannabis trade is the work still ahead.